Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Bullboard Posts
Comment by stockgurukingon Oct 31, 2012 10:40am
228 Views
Post# 20543972

RE: RE: Something is UP

RE: RE: Something is UP

The company has repeatedly publicly stated that Interim Phase II data will be announced in H2-2012.  Most recently in the update they circultated in October.  The full data set is due sometime in H2-2013 - most likely October/November as per the the Trials official Record Detail which states the estimated primary completion date is September 2013.  For a detailed record visit:

*

https://www.clinicaltrials.gov/ct2/show/NCT01565148?term=ico+therapeutics&rank=2

*

Financed below market?  Please provide an example of a company in the space that has financed at a premium in the past 12 months.  Note that JDRF (the worlds largest funder of diabetes research) is iCo's partner for the trial and has every optical (no pun intended) reason to ensure the trial is a success...the potential to "expand" this relationship exists.  Also, the company brought in $1.1 million non-dillutive from the Canadian government and the Gates Foundation for a "non-core" asset.

*

Other catalysts:

  • Regional partnership on 007
  • Further development of 009 via non-dillutive funding and potential partnerships
  • Going public event for 008 partner - Immune Pharamaceuticals is currently in the midst of listing on a US exchange and doing a large raise ($20-30 million).   ICO is owed seven figure milestones on this asset as early as H1 next year.
Bullboard Posts